Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1264-1266

  Oakley, Karen L ^a   Moore, Caroline B ^a   Denning, David W ^a,b,c  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ITRACONAZOLE; LIPOSOME; NYSTATIN;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; DRUG DELIVERY SYSTEM; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032911982     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1264     Document Type: Article

References (15)

1. Birch, M., G. Robson, D. Law, and D. W. Denning. 1996. Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect. Immun. 64:751-755.
2. Denning, D. W. 1994. Invasive aspergillosis in immunocompromised patients. Curr. Opin. Infect. Dis. 7:456-462.
3. Denning, D. W. 1996. Issues in the management of invasive aspergillosis. Ann. Med. Interne 146:106-110.
4. Gregoriadis, G. 1991. Overview of liposomes. J. Antimicrob. Chemother. 28 (Suppl. B):39-48.
5. Hay, R. J. 1994. Liposomal amphotericin B, AmBisome. J. Infect. 28(Suppl. 1):35-43.
6. Hazen, E. L., and R. Brown. 1951. Fungicidin, an antibiotic produced by a soil actinomycete. Proc. Soc. Exp. Biol. Med. 76:93-97.
7. Johnson, E. M., J. O. Ojwang, A. Szekely, T. L. Wallace, and D. W. Warnock. 1998. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob. Agents Chemother. 42:1412-1416.
8. Leenders, A. C. A. P., S. de Marie, M. T. ten Kate, I. A. J. M. Bakker-Woudenberg, and H. A. Verbrugh. 1996. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J. Antimicrob. Chemother. 38:215-225.
9. Mehta, R. T., R. L. Hopfer, L. A. Gunner, R. L. Juliano, and G. Lopez-Berestein. 1987. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31:1897-1900.
10. Morrison, V. A., R. J. Haake, and D. J. Weisdorf. 1994. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am. J. Med. 96:497-503.
11. Richardson, M. D. 1997. Lipid complexes of amphotericin B: the competitive picture. J. Med. Microbiol. 46:185-187.
12. Stanley, V. C., and M. P. English. 1965. Some effects of nystatin on the growth of four Aspergillus species. J. Gen. Microbiol. 40:107-118.
13. Stevens, D. A. 1994. Overview of amphotericin B colloidal dispersion (Amphocil). J. Infect. 28(Suppl. 1):45-59.
14. Swenson, C. E., W. R. Perkins, P. Roberts, I. Ahmad, R. Stevens, D. A. Stevens, and A. S. Janoff. 1998. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob. Agents Chemother. 42:767-771.
15. Wallace, T. L., V. Paetznick, P. A. Cossum, G. Lopez-Berestein, J. H. Rex, and E. Anaissle. 1997. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother. 41:2238-2243.